Clinical trial · Interventional
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography in Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was terminated due to lack of accrual.
Summary
Brief summary (as posted)
The primary objective of the study is to determine the progression-free survival \[PFS\] at 36 months for patients with Hodgkin lymphoma who achieve a complete metabolic response as demonstrated by a negative fluorodeoxyglucose (FDG)-PET scan after one cycle of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) who undergo abbreviated ABVD chemotherapy (3 cycles).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABVD chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Early Stage Disease
- description
- Group A
- interventionNames
- Drug: ABVD chemotherapy
- type
- OTHER
- label
- Advance Stage Disease
- description
- Group B
- interventionNames
- Drug: ABVD chemotherapy
Primary outcomes (1)
- measure
- 36-Month Progression-free Survival Rate
- timeFrame
- 36 months
- description
- Progression-free survival is defined as the length of time from study intervention to disease progression or death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented classical Hodgkin lymphoma according to the WHO Classification. Nodular lymphocyte predominant Hodgkin lymphoma is excluded * No prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma * Measurable disease must be present either on physical examination or imaging studies. Any tumor mass measurable in two dimensions and \> 2 cm is acceptable (or 1.5 cm if 0.5 cm slices are used as in spiral CT scans) * Age ≥ 18 * Patients must have at least one hypermetabolic lesion identifiable on initial PET scan * LVEF by ECHO or MUGA within institutional normal limits * Initial laboratory data should be compatible with the administration of standard doses of ABVD chemotherapy Exclusion Criteria: * Patient has no known HIV infection * Patient is non-pregnant and non-lactating. Due to the teratogenic potential of the agents used in this study, pregnant or nursing women may not be enrolled. Women and men of reproductive potential should agree to use an effective means of birth control * No other history of lymphoproliferative disorder or granulomatous disease
References
Publications (0)
Data not yet available